Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung

Modern Pathology

Volumn 10, Issue 12, 1997, Pages 1221-1227

  Bellotti, Marta ^a   Eisner, Boris ^a   De Lima, Andrea Paez ^a   Esteva, Hugo ^a   Marchevsky, Alberto M ^b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

DNA flow cytometry; Neural networks; Non small cell carcinoma of the lung; Prognosis; Tumor markers

Indexed keywords

CYCLINE; DNA; MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER RECURRENCE; CANCER REGRESSION; HUMAN; HUMAN TISSUE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ANTIGENS, NUCLEAR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; NEURAL NETWORKS (COMPUTER); NUCLEAR PROTEINS; PLOIDIES; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0344193099     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Annu Thorac Surg 1995;60:466-72.
2. Fontanini G, Pingitore R, Bigini D, Vignati S, Pepe S, Ruggiero A, et al. Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data. Am J Pathol 1992;141:1285-90.
3. Filderman AE, Silvestri GA, Gatsonis C, Luthringer DJ, Honig J, Flynn SD. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Resp Dis 1992;146:707-10.
4. Cibas ES, Melamed MR, Zaman MB, Kimmel M. The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer 1989;63:1552-6.
5. Tirindelli-Danesi D, Teodori L, Mauro F. Prognostic significance of flow cytometry in lung cancer. A 5-year study. Cancer 1987;60:844-51.
6. Volm M, Hahn EW, Mattern J, Muller T, Vogt-Moykopf I, Weber E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 4 1988;8:2923-8.
7. VoIm M, Bak M, Hahn EW, Mattern J, Weber E. DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma. Cytometry 1988;9:183-8.
8. Isobe H, Miyamoto H, Shimizu T. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 1990;65:1391-5.
9. Harpole DH Jr, Herndon JE II, Wolfe WG, Iglehart JD, Marx JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer, utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55: 51-6.
10. Miyamoto H, Harada M, Isobe H, Akita HD, Hneda H, Yamaguchi E, et al. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 1991;51:6346-50.
11. Gazdar AF. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 1992;69:1592-9.
12. Mørkve O, Halvorsen OJ, Stangeland L, Gulsvik A, Laerum D. Quantitation of biological tumors markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small cell lung cancer. Int J Cancer 1992;52:851-5.
13. Gail MH, Eagan RT, Felt R, Ginsberg R, Goodell B, Hill L, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the lung cancer study group. Cancer 1984;4:1802-13.
14. Mountain CF. The new international staging system for lung cancer. Surg Clin North Am 1987;67:925-35.
15. Sahin AA, Ro JY, El-Naggar AK, Lee JS, Ayala AG, Teague K. et al. Flow cytometric analysis of the DNA content of the non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer 1990;65:530-7.
16. Cagle PT. Molecular pathology of lung cancer and its clinical relevance. Monogr Pathol 1993;36:134-44.
17. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
18. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Ueda R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-6.
19. Ebina M, Steimberg SM, Mulshine JL, Linnoila RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-503.
20. Fontanini G, Macchiarini P, Pepe S, Ruggiero A, Harding M, Bigini D, et al. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative, non-small cell lung cancer. Cancer 1992;70:1520-7.
21. Esposito V, Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F, et al. Prognostic value of p53 in non-small cell lung cancer; relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 1997;28:233-7.
22. Castellano VM, Sotelo T, Ballestin C, Lopez-Encuentra A, Varela G. Analysis of proliferating cell nuclear antigen (PCNA) expression in 24 cases of primary non-small cell pulmonary carcinomas and correlation with survival. Arch Broncho 1996;32:127-31.
23. Wiethege T, Voss B, Muller KM. P53 accumulation and proliferating cell nuclear antigen expression in human lung cancer. J Cancer Res Clin Oncol 1995;121:371-7.
24. Oyama T, Mitsudomi T, Mizoue T, Ohgami A, Osaki T, Nakanishi R, et al. Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg Oncol 1995;4:83-9.
25. Kawai T, Suzuki M, Kono S, Shinomiya N, Rokutanda M, Takagi K, et al. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis. Cancer 1994;74:2468-75.
26. Vollmer RT. Multivariate statistical analysis for pathologists. Part I: the logistic model. Am J Clin Pathol 1996;105:115-26.
27. Hamilton PW, Bartels PH, Montironi R, Anderson N, Thompson D. Improved diagnostic decision-making in pathology: do inference networks hold the key? J Pathol 1995;175:1-5.
28. Bartels PH, Thompson D, Weber. Data analysis. In: Marchevsky AM, Bartels PH, editors. Image analysis: a premier for pathologists. New York, NY: Raven Press; 1994. p 207.
29. World Health Organization. Histologic typing of lung tumors In: International histological classification of tumors. 2nd ed. Vol. 1. Geneva, Switzerland: World Health Organization; 1981.
30. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method of analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
31. Truong HM, Morimoto R, Walts AD, Marchevsky AM. Neural networks as an aid in the diagnosis of lymphocyte-rich effusions. Annu Quant Cytol Histol 1995;17:48-54.
32. Erler BS, Hsu L, Truong HM, Petrovic LM, Kim SS, Huh MH, et al. Image analysis and diagnostic classification of hepatocellular carcinoma using neural networks and multivariate discriminant functions. Lab Invest 1994;71:446-51.
33. Dybowski R, Gant V. Artificial neural networks in pathology and medical laboratories. Lancet 1995;346:1203-7.
34. Becker RL. Computer-assisted image classification: use of neural networks in anatomic pathology. Cancer Lett 1994; 77:111-7.
35. O'Leary TJ, Mikel UV, Becker RL. Computer-assisted image interpretation: use of a neural network to differentiate tubular carcinoma from sclerosing adenosis. Mod Pathol 1992;5: 402-5.
36. Mehdi B, Stacey D, Harauz G. A hierarchical neural network assembly for classification of cervical smears in automated screening. Anal Cell Pathol 1994;7:171-80.
37. Reibnegger G, Weiss G, Werner-Felmayer G, Judmaier G, Wachter H. Neural networks as a tool for utilising laboratory information: comparison with linear discriminant analysis and with classification and regression trees. Proc Natl Acad Sci U S A 1991;88:11330-426.
38. Baxt WG. Application of artificial neural networks to clinical medicine. Lancet 1995;346:1135-8.
39. Cross SS, Harrison RF, Kennedy RL. Introduction to neural networks. Lancet 1995;346:1075-9.
40. Astion ML, Wilding P. Application of neural networks to the interpretation of laboratory data in cancer diagnosis. Clin Chem 1992;38:34-8.
41. Sietsma J, Dow RJF. Creating artificial neural networks that generalize. Neural Networks 1991;1:67-79.
42. Marchevsky AM, Afari A, Truong HM, Said JW. Image analysis and multivariate statistics for the classification of non-Hodgkin's lymphomas: use of a commercially available microcomputer-based image analysis system. J Surg Pathol 1995;1:19-29.